We also previously demonstrated the role of the MALAT1/miR-26/PFKFB3 axis in the pathogenesis of early-onset preeclampsia (EOPE) and proposed that targeting PFKFB3 to drive glycolysis is a promising therapeutic strategy for EOPE [15]. Here, PFKFB3 is linked to preeclampsia.